1. EPWORTH Knowedge Bank
  2. Academic & Clinical
  3. Cancer Services
Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/2051
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPrince, Miles-
dc.contributor.otherAttal, Michel-
dc.contributor.otherRichardson, Paul-
dc.contributor.otherRajkumar, S.Vincent-
dc.contributor.otherSan-Miguel, Jesus-
dc.contributor.otherBeksac, Meral-
dc.contributor.otherSpicka, Ivan-
dc.contributor.otherLeleu, Xavier-
dc.contributor.otherSchjesvold, Fredrik-
dc.contributor.otherMoreau, Philippe-
dc.contributor.otherDimopoulos, Meletios-
dc.contributor.otherHuang, Jeffrey-
dc.contributor.otherMinarik, Jiri-
dc.contributor.otherCavo, Michele-
dc.contributor.otherMacé, Sandrine-
dc.contributor.otherCorzo, Kathryn-
dc.contributor.otherCampana, Frank-
dc.contributor.otherLe-Guennec, Solenn-
dc.contributor.otherDubin, Franck-
dc.contributor.otherAnderson, Kenneth-
dc.contributor.otherstudy group, ICARIA-MM-
dc.date2019-11-
dc.date.accessioned2021-11-23T01:31:30Z-
dc.date.available2021-11-23T01:31:30Z-
dc.date.issued2019-11-
dc.identifier.citationLancet (London, England), 394(10214), 2096–2107.en_US
dc.identifier.issn0140-6736en_US
dc.identifier.issn1474-547Xen_US
dc.identifier.urihttp://hdl.handle.net/11434/2051-
dc.description.abstractIsatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone. The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and dexamethasone compared with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma.en_US
dc.publisherElsevieren_US
dc.subjectIsatuximaben_US
dc.subjectPomalidomideen_US
dc.subjectLow-Dose Dexamethasoneen_US
dc.subjectMultiple Myelomaen_US
dc.subjectRelapsed and Refractory Multiple Myeloma (ICARIA-MM)en_US
dc.subjectPhase 3 studyen_US
dc.subjectMonoclonal Antibodyen_US
dc.subjectAntitumour Activityen_US
dc.subjectProgression-Free Survival (PFS)en_US
dc.subjectMedian Progression-Free Survivalen_US
dc.subjectTreatment-Emergent Adverse Eventsen_US
dc.subjectProteasome Inhibitoren_US
dc.subjectLenalidomideen_US
dc.subjectIntention-to-Treat Populationen_US
dc.subjectInteractive response technologyen_US
dc.subjectEpworth Centre for Immunotherapies and Snowdome Laboratoriesen_US
dc.subjectMolecular Oncology and Cancer Immunologyen_US
dc.subjectCancer Services Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.titleIsatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.en_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1016/S0140-6736(19)32556-5en_US
dc.identifier.journaltitleThe Lanceten_US
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/31735560/en_US
dc.description.affiliatesInstitut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.en_US
dc.description.affiliatesJerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: paul_richardson@dfci.harvard.edu.en_US
dc.description.affiliatesDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.en_US
dc.description.affiliatesClinical and Translational Medicine, Clínica Universidad de Navarra, Navarra, CIMA, IDISNA, CIBER-ONC, Pamplona, Spain.en_US
dc.description.affiliatesDepartment of Hematology, Ankara University, Ankara, Turkey.en_US
dc.description.affiliates1st Department of Medicine, Department of Hematology, First Faculty of Medicine Charles University and General Hospital in Prague, Prague, Czech Republic.en_US
dc.description.affiliatesDepartment of Haematology, CHU La Milétrie-Poitiers, Poitiers, France.en_US
dc.description.affiliatesOslo Myeloma Center, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway.en_US
dc.description.affiliatesHematology Department, CHU Nantes, Nantes, France.en_US
dc.description.affiliatesDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.en_US
dc.description.affiliatesDepartment of Hematology, National Taiwan University Hospital, Taiwan.en_US
dc.description.affiliatesDepartment of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republicen_US
dc.description.affiliatesDepartment of Experimental, Diagnostic and Specialty Medicine, Seràgnoli Institute of Hematology, University of Bologna, Bologna, Italy.en_US
dc.description.affiliatesSanofi Research And Development, Vitry-Sur-Seine, France.en_US
dc.description.affiliatesSanofi-Genzyme Oncology, Cambridge, MA, USA.en_US
dc.description.affiliatesJerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.en_US
dc.type.studyortrialRandomised, Multicentre, Open-label, Phase 3 Studyen_US
dc.type.contenttypeTexten_US
Appears in Collections:Cancer Services
MOCI

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.